Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Menopauseens rolle i termoregulering

1. oktober 2026 opdateret af: W. Larry Kenney, Penn State University

Estrogens indflydelse på de termoregulerende reaktioner på varmestress i kvinder før og postmenopausale kvinder

The frequency and severity of heat waves has increased in the last decades. Older adults (over 65 years) have impaired responses to heat stress making them at increased risk for adverse events. Previous heat waves report that women over 65 experience worse health outcomes than any other age group and age matched men.

Aging and reproductive hormones, specifically estrogen, independently alter responses to heat stress. However, the combined effects of low estrogen following menopause and aging on the response to heat stress are unknown. In this study, the investigators will identify the role of estrogen in pre and post menopausal women on thermoregulatory responses to heat stress.

Studieoversigt

Detaljeret beskrivelse

Premenopausal and postmenopausal women will be recruited and different interventions will be given to each group. To mimic a postmenopausal hormone profile, premenopausal women will be given a GnRH antagonist, which acutely reduces estrogen concentrations. This induces a temporary post-menopausal state without compounding aging effects. Postmenopausal women will be given a transdermal estradiol patch to acutely raise estrogen concentrations. Supplementing estrogen in postmenopausal women allows for the effect of menopausal low estrogen concentration to be removed from the physiological effects of aging.

Subjects sign an informed consent form and undergo a medical screening prior to participation. The screening includes a physical exam, anthropometry, chemical and lipid profiles.

Each subject will complete 6 (3 for each treatment) experimental trials. For each intervention, participants will complete one passive heating experiment first, followed by two active heating experiments.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

24

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: W. Larry Kenney, Ph.D.
  • Telefonnummer: 814-863-1672
  • E-mail: w7k@psu.edu

Undersøgelse Kontakt Backup

Studiesteder

    • Pennsylvania
      • University Park, Pennsylvania, Forenede Stater, 16802
        • Rekruttering
        • Noll Laboratory
        • Kontakt:
          • W. Larry Kenney, Ph.D.
          • Telefonnummer: 814-863-1672
          • E-mail: w7k@psu.edu
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

42 år til 64 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  • Women ages 42-64

Exclusion Criteria:

  • Chron's disease, diverticulitis, or similar gastrointestinal disease
  • Abnormal resting exercise electrocardiogram (ECG)
  • Tobacco use
  • High-risk determined by the Atherosclerotic Cardiovascular Disease (CVD) Risk Factor
  • Assessment
  • Using hormone therapy
  • Using hormonal contraceptives

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Premenopausal estrogen suppression

Participants take a cellulose placebo tablet for 4 days prior to baseline testing and continue until experimental visits are complete. Following completion of placebo testing, participants begin taking 400 mg/day Elagolix for 4 days prior to testing and continue until experimental visits are complete.

2 x 200 mg tablet

Andre navne:
  • Orilissa

placebo tablet

Eksperimentel: Postmenopausal estrogen supplementation

Participants wear a transdermal estradiol patch or placebo patch for 5 days prior to testing and continue until experimental visits are complete. After 48 hr washout, participants then wear the alternative treatment for 5 days prior to testing until experimental visits are complete.

0.05 mg/day patch

placebo patch

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Skin Blood Flow
Tidsramme: Monitored continuously during both 3 hour passive heating experiments (Visit 1 and Visit 3 approx 3 weeks)

Skin blood flow response to whole body heating is continuously monitored

Monitored continuously during both 3 hour passive heating experiments (Visit 1 and Visit 3 approx 3 weeks)
Local Sweat Rate
Tidsramme: Monitored continuously during both 3 hour passive heating experiments (Visit 1 and Visit 3 approx 3 weeks)

A small sweat capsule is placed on the forearm for the duration of whole body heating.

Monitored continuously during both 3 hour passive heating experiments (Visit 1 and Visit 3 approx 3 weeks)
Core Temperature
Tidsramme: Monitored continuously during all 3 hour experimental visits (6 total average of 3 weeks)

Changes in body temperature are measured through a telemetry pill swallowed before each experiment.

Monitored continuously during all 3 hour experimental visits (6 total average of 3 weeks)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Body Mass
Tidsramme: Baseline and following 3 hr experimental visit (6 total visits for study completion, an average of 3 weeks)

Body mass is measured on a scale.

Baseline and following 3 hr experimental visit (6 total visits for study completion, an average of 3 weeks)
Skin Temperature
Tidsramme: Calculated continuously for the duration of each 3 hr experimental visit (6 total visits for study completion, an average of 3 weeks)

Mean skin temperature is calculated from a weighted average of skin temperature from 4 different sites.

Calculated continuously for the duration of each 3 hr experimental visit (6 total visits for study completion, an average of 3 weeks)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: W. Larry Kenney, Ph.D., The Pennsylvania State University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. marts 2025

Primær færdiggørelse (Anslået)

1. december 2026

Studieafslutning (Anslået)

1. december 2026

Datoer for studieregistrering

Først indsendt

15. januar 2025

Først indsendt, der opfyldte QC-kriterier

22. januar 2025

Først opslået (Faktiske)

29. januar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

2. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • Study 25435

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner